Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.
Zunich
K M
KM
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.
Lane
H C
HC
Davey
R T
RT
Falloon
J
J
Polis
M
M
Kovacs
J A
JA
Masur
H
H
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use* / Q000633:toxicity; D015686:Gene Products, env / Q000276:immunology / Q000627:therapeutic use* / Q000633:toxicity; D016655:HIV Core Protein p24 / Q000276:immunology / Q000627:therapeutic use* / Q000633:toxicity; D019302:HIV Envelope Protein gp160; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016233:Immunotherapy, Active; D011498:Protein Precursors / Q000276:immunology / Q000627:therapeutic use* / Q000633:toxicity; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use / Q000633:toxicity; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use* / Q000633:toxicity
D016915:AIDS Vaccines; D015686:Gene Products, env; D016655:HIV Core Protein p24; D019302:HIV Envelope Protein gp160; D011498:Protein Precursors; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic